As the Australian PI I have to say I agree. PISCES took 10 years to do as best we could on minimal funding. The result is what it is - we will try to look further in to the data but given the low cost/ low risk what would be the point in doing another larger study? It would be hard to find funding

Recall only a few years ago that the late breaking trials session often has post hoc observation analyses or another negative HD or AKI trial. Indeed it is fantastic. More tomorrow…

Yes Finerenone okay given the data already out. Plus it will likely get a HF indication by as well. For Atacicept even with the positive slope data one trial in 200 patients won’t cut it I suspect in Australia.

While I agree, here in Australia the drugs will not get funded by the govt without the harder endpoints unless of course the price is okay which of course is not going to happen. It’s exciting to see all these new therapeutics but unless the cost comes down I doubt we will see them in Australia soon

Agree. I gave talk to my ID colleagues who still use CG for dosing at their request. They also mentioned another big problem in ID is Augmented renal clearance of antibiotics in patients with burns etc. Being a nephrologist hadn’t really concerned myself with kidney function that’s too good 😂

Yep. No way will be available in Australia. Is it available for C3GN there?

Yes. Will no doubt be further work to assess this in more detail in time

Not sure. Mike didn’t have time to go over in detail.

It’s very interesting that this is being done. Shellie and I plus a few others are looking at this more closely Hopefully will have some nice data to get out there.